Back

Low-density lipoprotein cholesterol reduction with evolocumab and its use in clinical practice: evidence from swedish national register data

26 August 2022 (15:50 - 16:00)
Organised by:
Congress Presentation Part of: Lipid-lowering by PCSK9 modulation: what’s new? Lipid-Lowering Agents ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Professor Maria Svensson

Uppsala University Hospital, Uppsala (Sweden)

4 More presentations in this session

Presentation thumbnail
PCSK-9-inhibitor therapy improves endothelial function in high-risk patients with cardiovascular disease
Doctor D. Kannenkeril (Erlangen, DE)
Abstract Slides Video
Presentation thumbnail
Impact of alirocumab added to high-intensity statin therapy on platelet function in AMI patients: a pre-specified substudy of the randomized, placebo-controlled PACMAN-AMI trial
Doctor L. Raber (Bern, CH)
Abstract Slides Video
Presentation thumbnail
Evolocumab treatment is associated with early and sustained reductions in low-density cholesterol (LDL-C) over 30 months: final results from the pan-European observational HEYMANS registry
Professor K. Ray (London, GB)
Abstract Slides Video
Presentation thumbnail
High individual variability in LDL-reductions after inclisiran administration in a "real-world setting"
Professor O. Weingaertner (Jena, DE)
Abstract Slides Video

Access the full session

Session thumbnail
Lipid-lowering by PCSK9 modulation: what’s new?

The Event

Event poster

ESC Congress 2022

26 August 2022 15:50 CET
You may be interested in
thumbnail
Congress Presentation
Breaking through: CETP inhibitors and the future of lipid therapy
thumbnail
Congress Presentation
Redrawing the map: why we must cross boundaries in lipid management
thumbnail
Congress Presentation
Introduction

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources